Expanded collaboration with Nationwide Children's Hospital adds new funding and a third therapeutic candidate (CLN-301) to Alcyone's diversified portfolio of precision CNS therapeutics and delivery ...
Biogen has agreed to divest Alcyone Therapeutics' remaining therapeutic assets to a new independent company. (z_wei/iStock/Getty Images Plus) Biogen has given Alcyone Therapeutics a starring role in ...
Alcyone, which has over seven years of experience in digital marketing, has launched a new hyper-local content marketing service for ketamine therapy providers, and other alternative therapy centers.
CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop ...
Alcyone Lifesciences Receives FDA Clearance for the Alivio System for the Treatment of Hydrocephalus
LOWELL, Mass., Nov. 15, 2017 /PRNewswire/ -- Alcyone Lifesciences, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the Alivio Ventricular Catheter & Flusher System (Alivio ...
The PIERRE pivotal study (https://clinicaltrials.gov/ct2/show/NCT05866419) will enroll up to 90 patients and will be conducted in two stages. The first stage is ...
Alcyone's ThecaFlex DRx™ System is an implantable medical device in development to enable routine subcutaneous administration of therapeutics to the cerebrospinal fluid First stage of the pivotal ...
Alcyone's ThecaFlex DRxTM System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- biogen Inc. (Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results